Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc. (collectively, Teva) have agreed to pay $450 million to resolve allegations that they violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), according to the U.S. Department of Justice (DOJ).
Teva is an Israeli company, with U.S. headquarters in Parsippany, New Jersey, and is the largest generic drug manufacturer in the United States, according to the DOJ.
The settlement amount was based on Teva’s ability to pay, the DOJ said.
The settlement addresses two alleged kickback schemes.
First, Teva allegedly violated and conspired to violate the AKS and FCA by covering Medicare patients’ copays for the multiple sclerosis drug Copaxone from 2006 through 2017, while steadily increasing the drug’s price….